How Accurate are Budget Impact Predictions for New Drugs? An Empirical Analysis

Michael S. Broder, MD, MSHS\(^1\), Jenelle M. Zambrano, DNP, CNS, RN\(^1\), Jackie Lee, BS\(^1\); Richard S. Marken, PhD\(^2\)

\(^1\) Partnership for Health Analytic Research, LLC, Beverly Hills, CA; \(^2\) RSM Consulting, Los Angeles, CA

**BACKGROUND**
- Concern about the prices of newly launched drugs is rising among the public and among healthcare payers.
- Various media reports often quote estimates of the impact new drugs are expected to have on healthcare costs.
- The accuracy of these estimates has not been rigorously studied.

**OBJECTIVE**
- To evaluate the accuracy of pre-launch predictions of the budget impact of newly approved drugs.

**METHODS**

**Study Design**
We identified a sample of newly developed drugs that received FDA approval in the last 5 years. We searched for pre-launch budget impact estimates and post-launch actual budget impact for these drugs and compared them to evaluate accuracy. We grouped pre-launch estimates into those by individual analysts, which we termed “informal” analyses, and those that presented a summary of multiple analysts’ estimates, or were from governmental bodies, payers, or other large healthcare organizations, which we termed “formal.” We then examined factors that might affect the accuracy of the pre-launch budget impact estimates.

**Study Measures**
- Pre-launch budget impact estimate
  - **Sources**: Medical news publications, non-profit research organizations, and news reports
  - **Time frame**: Launch year-1 (e.g., if drug launch was in 2013, then 2012 was used)
  - **Keywords**: Trade/generic name, estimated sales, predicted sales, revenue, annual sales, sales forecast, launch year+1, report, US, United States
- Post-launch actual budget impact (sales)
  - **Source**: Sales revenue from manufacturers’ earnings reports
  - **Time frame**: Year of predicted sales estimate (e.g., if pre-launch estimated predicted sales for 2015, then 2015 was used)
- **Ratio of Predicted Cost (P) to Actual Cost (A)**: P/A
  - **Predicted cost** = pre-launch budget impact estimate of a drug
  - **Actual cost** = post-launch actual budget impact of a drug

**Statistical Analysis**
- P/A determined the degree of over or under estimation of predicted to actual budget impact. Predicted cost was an accurate estimate of actual cost if P/A = 1.

**RESULTS**
- We identified 24 pre-launch estimates for 14 drugs.
- Multiple budget impact estimates were found for several drugs (Opdivo, Viekira Pak, Repatha, Praluent, PCSK9 combined, Cosentyx, and Sovaldi).
- Predicted and actual costs are shown in Fig. 1.

**CONCLUSIONS**
- For a sample of recently launched drugs, the pre-launch predictions of their budget impact were considerable overestimates of their actual budget impact, although there were some notable underestimates.
- For every $1 of predicted cost, there was $1 of actual cost to the healthcare system.
- Neither drug price nor source of budget impact estimate appeared to be associated with the accuracy of the estimate.
- Using an older but larger data set and slightly different methodology, a prior study focusing only on equity analysts’ forecasts found forecasts were commonly more than 200% of actual sales.\(^1\)
- Potential reasons for this systematic bias may include over-optimism on the part of analysts\(^2,3\).
- Bias may also result from the desire to maximize the media impact of pre-launch sales estimates.
- Overestimating budget impact may lead to early access restrictions, higher copays, and other changes in plan design that would ultimately impact patients.
- Predictions of the cost impact of new drugs should be constantly evaluated in order to improve them.

**REFERENCES**

Presented at AMCP NEXUS, October 3-6, 2016, National Harbor, MD

Research was conducted by Partnership for Health Analytic Research, LLC. This study was sponsored by Amgen.